<DOC>
	<DOCNO>NCT02748967</DOCNO>
	<brief_summary>The purpose study assess safety tolerability different dos ExPEC4V ( JNJ-63871860 ) healthy Japanese participant great equal [ &gt; = ] 20 year age .</brief_summary>
	<brief_title>A Study Evaluate Safety Immunogenicity Different Doses ExPEC4V ( JNJ-63871860 ) Healthy Japanese Adult Participants</brief_title>
	<detailed_description>This Phase 1 double-blind ( neither Investigator participant know treatment ) , randomize ( study medication assign chance ) , placebo-controlled ( inactive substance compare medication test whether medication real effect clinical study ) parallel group , single center study healthy Japanese participant age great equal [ &gt; = ] 20 year . A target approximately 48 participant enrol stratified accord age 2 group : 24 participant &gt; = 20 less [ &lt; ] 50 year age 24 participant &gt; = 50 year age . Both group randomize single vaccination 1 3 study dose level ExPEC4V placebo ( vaccine buffer ) . Participants enrol dose ascend approach . Blood sample draw Days 1 ( prevaccination ) , 15 30 assessment immunogenicity . The study duration per participant approximately 38 day ( Screening period postvaccination follow-up include ) . Participants ' safety monitor throughout study .</detailed_description>
	<criteria>Each participant must sign Informed Consent Form ( ICF ) indicate understands purpose , procedure require study willing participate study Participant must man woman great equal [ &gt; = ] 20 year age day sign ICF A female participant must agree donate egg ( ovum , oocytes ) purpose assist reproduction least 3 month study vaccine administration . A male participant must agree donate sperm least 3 month study vaccine administration Participant must body mass index ( BMI : weight kg divide square height meter ) less equal [ &lt; = ] 30.0 kg/m^2 A male participant sexually active woman childbearing potential vasectomy must agree use double barrier method birth control eg , either condom spermicidal foam/gel/film/cream/suppository partner use occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/suppository Participant history neoplastic disease ( exclude nonmelanoma skin cancer successfully treat ) within past 5 year history hematological malignancy Participant current history autoimmune disease Participant receive investigational drug ( include investigational vaccine ) within 90 day vaccination study currently enrol investigational study Participant receive treatment immunoglobulin blood product 4 month vaccination study plan receive treatment study Participant know suspect congenital acquired immunodeficiency ( include leukemia , human immunodeficiency virus [ HIV ] seropositivity ) , receive immunosuppressive therapy ( cyclosporine , anticancer chemotherapy , radiation therapy , cytotoxic drug ) within precede 6 month ; longterm systemic corticosteroid therapy ( prednisone equivalent ) 2 consecutive week within past 3 month , chronic active hepatitis B hepatitis C infection , document hepatitis B surface antigen ( HBsAg ) hepatitis C antibody , respectively</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Healthy</keyword>
	<keyword>ExPEC4V</keyword>
	<keyword>JNJ-63871860</keyword>
	<keyword>Safety</keyword>
</DOC>